Greg Tietjen is a co-founder and the CEO of Revalia Bio where he and the team are working to modernize biomedical innovation by pioneering a new human-data-centered approach. Outside his role at Revalia, Greg is a leading voice on the future of biomedical innovation. His perspective is informed by a unique multi-disciplinary background spanning the humanities, science & technology. He began his career with a degree in Literature and spent several years training to be a musician before a severe injury forced him to change course. Greg then pivoted to science where he earned his PhD in Biophysics at the University of Chicago before completing Postdoctoral training in the Biomedical Engineering at Yale University. Greg was then an Assistant Professor in the Yale School of Medicine, where his lab was highly decorated and internationally recognized as a world leader in Human Organ Research. In March of 2023, Greg walked away from his tenure track position at Yale to go full time into Revalia.
Areas of Expertise
Biomedical Engineering, Biophysics, Entrepreneurship, Healthcare Innovation, Translational Science